In fact, valve surgery candidates typically present a left ventricular hypertrophy, i.e., an increase of their cardiac muscle mass, which in turn could proportionally increase the post-operative cTnT value (24–26). The gene discussed is TNNT2; the disease is left ventricular hypertrophy.